Printer Friendly

ALAN A. STEIGROD NAMED TO THE BOARD OF DIRECTORS OF IMMUNOGEN, INC.

ALAN A. STEIGROD NAMED TO THE BOARD OF DIRECTORS OF IMMUNOGEN, INC.
 CAMBRIDGE, Mass., April 30 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of Alan A. Steigrod to its board of directors. Steigrod brings to ImmunoGen over 30 years of senior management experience in the pharmaceutical industry, most recently as executive vice president of Glaxo, Inc.
 "We are pleased and excited to have Alan Steigrod join our board of directors," states ImmunoGen Chairman, President and CEO, Mitchel Sayare. "His skills and experience in marketing, sales and management give ImmunoGen a valuable new resource as we gear up our commercialization efforts."
 In his position as executive vice president, Steigrod was chairman of Glaxo's Operating Committee. From 1985 to 1991, he was a member of Glaxo's Board of Directors. Prior to joining Glaxo in 1981, Steigrod was national sales director for Boehringer Ingleheim Ltd. He also held various domestic and international sales and marketing positions with Eli Lilly and Company from 1961 to 1977.
 Steigrod is a former chairman of the marketing section of the Pharmaceutical Manufacturers Association. He holds a B.S. in Pharmacy from the Temple University School of Pharmacy.
 ImmunoGen, Inc. is a Cambridge, Mass.-based biotechnology company that develops biopharmaceuticals, primarily for the treatment of cancer. The company produces proprietary toxins, drugs and biologicals conjugated to highly specific monoclonal antibodies which search out and destroy cancer cells. ImmunoGen currently has three products in human clinical trials in the United States, Canada and Europe, and has filed with the U.S. Food and Drug Administration to begin human testing of its fourth product.
 -0- 4/30/92
 /CONTACT: Mark Ratner of ImmunoGen, 617-661-9312/
 (IMGN) CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER


DD -- NE002 -- 4743 04/30/92 08:37 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:295
Previous Article:CAMBRIDGE BIOTECH REPORTS FIRST QUARTER 1992 RESULTS
Next Article:NAR'S HOUSING AFFORDABILITY INDEX SUSTAINS HEALTHY LEVEL


Related Articles
ZYNAXIS APPOINTS ALAN STEIGROD TO BOARD OF DIRECTORS
ALAN STEIGROD NAMED CORTEX PRESIDENT & CHIEF EXECUTIVE OFFICER
CORTEX RETAINS VECTOR SECURITIES AS FINANCIAL ADVISOR
JEROME M. ARNOLD JOINS CORTEX BOARD OF DIRECTORS
CORTEX EXTENDS CLASS A, CLASS B AND CLASS C WARRANTS
CORTEX APPOINTS DAVIS TEMPLE, Ph.D., TO BOARD OF DIRECTORS
CORTEX PROVIDES PRODUCT DEVELOPMENT UPDATE
CORTEX STOCKHOLDERS APPROVE REVERSE STOCK SPLIT; DR. GARY S. LYNCH ELECTED TO BOARD OF DIRECTORS
CORTEX APPOINTS DR. GARY ROGERS VICE PRESIDENT, PHARMACEUTICAL DISCOVERY
CORTEX ANNOUNCES MANAGEMENT CHANGES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters